Immunohistochemical analysis showed that IRF4 expression was observed in a variety of B-cell lymphomas including Diffuse large B-cell lymphomas (DLBCLs), marginal zone lymphomas (MZLs) and B-cell chronic lymphocytic leukemias (B-CLL) or small lymphocytic lymphomas (SLL) strongly suggesting its involvement with various myeloid and lymphoid malignancies [66]. Here, IRF4 is linked to marginal zone lymphoma.